ESCORT-1ST
Regimen
- Experimental
- camrelizumab + paclitaxel/cisplatin
- Control
- placebo + paclitaxel/cisplatin
Population
Previously untreated advanced or metastatic ESCC
Key finding
mOS 15.3 vs 12.0 mo (HR 0.70, 95% CI 0.56-0.88, p=0.001); mPFS 6.9 vs 5.6 mo (HR 0.56, 95% CI 0.46-0.68, p<0.001); met both coprimary endpoints
Source: PMID 34519801